NASDAQ
Representative Julie Johnson (D-Texas) recently sold shares of AbbVie Inc. (NYSE: ABBV). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,...
Caldwell Trust Co bought a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commiss...
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materiall...
With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and expanding into other therapeutic areas....
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business ...
The rapid rise of artificial intelligence (AI) has transformed the stock market in recent years, powering massive gains in technology giants and growth-oriented investments. At the same time, dividend...
Adage Capital Partners GP L.L.C. decreased its stake in AbbVie Inc. (NYSE: ABBV) by 10.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exc...
Ameriprise Financial Inc. decreased its stake in AbbVie Inc. (NYSE: ABBV) by 25.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Com...
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending...
One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff....
No price data available for this timeframe.